SPARC · NSE
Sun Pharma Advanced Research Company Limited
₹193.92
+0.39% (+₹0.76)
Prev. close
₹193.16
Volume
6,82,997
Delivery %
47.9%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Sun Pharma Advanced Research for intraday trading, recommending a buy at ₹205 with a target of ₹220 and a sto…” | Vaishali ParekhPrabhudas Lilladher | Sun Pharma Advanced Research | PENDING |
Fundamentals
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Anilkumar Raghavan
Headquarters
Mumbai
Employees
279
Website
sparc.lifeExchange
View on NSE ↗Key stats
Market cap
₹6,320.38 Cr
P/E ratio (TTM)
4.0
EPS (TTM)
₹48.83
Beta (1Y · daily vs NIFTY 50)
1.85
Beta (5Y · monthly vs NIFTY 50)
1.67
Shares float
9.77 Cr
EPS · quarter ended Jun 2026
₹-0.64
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹252.96 Cr | ₹137.25 Cr | ₹238.78 Cr | ₹75.55 Cr | ₹71.77 Cr | ₹39.15 Cr | |
| EBITDA | ₹-129.57 Cr | ₹-179.91 Cr | ₹-203.18 Cr | ₹-373.13 Cr | ₹-321.85 Cr | ₹1,594.81 Cr |
| ₹-151.14 Cr | ₹-203.40 Cr | ₹-222.58 Cr | ₹-387.21 Cr | ₹-342.51 Cr | ₹1,553.20 Cr | |
| Diluted EPS | ₹-5.77 | ₹7.73 | ₹-7.82 | ₹-11.93 | ₹-10.55 | ₹47.86 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹229.69 Cr | ₹280.08 Cr | ₹830.13 Cr | ₹515.04 Cr | ₹335.53 Cr | ₹2,170.88 Cr | |
| — | ₹79.21 Cr | ₹15.68 Cr | ₹57.66 Cr | ₹265.13 Cr | ₹557.80 Cr | |
| Stockholders' equity | — | ₹31.23 Cr | ₹512.78 Cr | ₹125.76 Cr | ₹-216.95 Cr | ₹1,338.83 Cr |
Fixed assets, CWIP, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹-69.12 Cr | ₹-429.19 Cr | ₹-360.29 Cr | ₹-238.78 Cr | |
| Investing cash flow | — | — | ₹-548.28 Cr | ₹391.53 Cr | ₹157.66 Cr | ₹-23.50 Cr |
| — | — | ₹616.76 Cr | ₹42.41 Cr | ₹199.26 Cr | ₹261.39 Cr | |
| Capital expenditure | — | — | ₹-15.39 Cr | ₹-26.51 Cr | ₹-10.34 Cr | ₹-23.83 Cr |
| End cash position | — | — | ₹58.36 L | ₹5.33 Cr | ₹1.96 Cr | ₹1.16 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Dec 21(2Q) | Mar 22–Sep 22(4Q) | Dec 22 | Jan 23–Jun 26(16Q) |
|---|---|---|---|---|
| Promoter | 68.10% | 69.09% | 68.22% | 65.67% |
| Public | 31.90% | 30.91% | 31.78% | 34.33% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Sun Pharma Advanced Research Company Limited | ₹6,320.38 Cr | ₹193.92 | 4.0 | 4.72 | 116.0% | 0.42 | -45.5% | +34.8% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 21
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
7 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.